Kadderum

Eltrombopag, the active ingredient in Kadderum, is a thrombopoietin receptor agonist presented as an oral formulation for oral use. It is indicated for the treatment of immune thrombocytopenia, severe aplastic anemia, and hepatitis C‑associated thrombocytopenia in appropriate patient populations.

GNH USA supplies Kadderum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Eltrombopag acts on the thrombopoietin pathway to increase platelet production in several hematologic disorders.

- Immune thrombocytopenia (ITP): raises platelet counts in patients with chronic ITP. - Severe aplastic anemia: supports hematopoiesis by stimulating platelet formation. - Hepatitis C‑associated thrombocytopenia: improves platelet levels in patients with liver‑related low platelet counts.

Adverse reactions may occur with any medication and should be monitored by the prescribing clinician.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, usually transient. - Fatigue: general tiredness or lack of energy. - Elevated liver enzymes: mild increases in hepatic transaminases.

Serious or Rare Side Effects: - Thromboembolic events: risk of clot formation in veins or arteries. - Severe liver injury: rare cases of hepatitis or hepatic failure. - Bone marrow fibrosis: uncommon development of fibrotic changes in marrow.

Patients should be evaluated for safety considerations before and during therapy.

- Dose adjustment: monitor platelet counts regularly and adjust dose accordingly. - Liver function: assess hepatic enzymes before initiation and periodically thereafter. - Thrombosis risk: evaluate individual risk factors for clot formation. - Pregnancy and lactation: use only if potential benefit outweighs potential risk, as safety data are limited. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Eltrombopag may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce eltrombopag exposure. - Anticoagulants (e.g., warfarin): may increase bleeding risk when platelet counts rise rapidly.

Moderate Interactions (Monitor Closely): - Antacids containing magnesium or aluminum: can decrease absorption; separate dosing by at least two hours. - Live vaccines: efficacy may be reduced; consider timing of vaccination. - Other thrombopoietin receptor agonists: additive effect on platelet counts; monitor closely for thrombosis.